Owing to the reduced risk of symptomatic and nocturnal hypoglycemia of LAIA versus IAHI as demonstrated in clinical studies2–5, LAIA is generally preferable in clinical practice compared to IAHI, such as human neutral protamine Hagedorn (NPH) insulin. This evidence concerns the gene INS and Hypoglycemia.